India, Feb. 4 -- Organisation nod for Durvalumab in gastric cancer therapy
AstraZeneca Pharma India Ltd has secured approval from the Central Drugs Standard Control Organisation (CDSCO) for the use of Durvalumab in combination with chemotherapy for the treatment of gastric and gastroesophageal junction cancer.
The regulator has approved Durvalumab alongside the FLOT chemotherapy regimen — comprising fluorouracil, leucovorin, oxaliplatin and docetaxel — making it the first and only perioperative immunotherapy option for adult patients with resectable gastric or gastroesophageal junction adenocarcinoma.
The company noted that nearly half of such cancer cases are diagnosed at a stage where surgery is possible, with peri-operative...